主页文献库搜索
K562/GM-CSF vaccination reduces tumor burden, including achieving molecular r...

Smith(B),Kasamon(Y L),Miller(C B),Chia(C),... J Clin Oncol 0000-00-00

...mos. Pts were on IM for a median of 37 (13-53) mos prior. 4 of 19 pts had FISH pos as their best previous response (BPR)...

A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RN...

Marcucci(G),Klisovic(R B),Wei(W),Liu(S),Pa... J Clin Oncol 0000-00-00

...mos), 6 had complete remission (CR) and 1 incomplete CR (no disease and incomplete blood count recovery). In cohort II, ...

Gastrointestinal stromal tumors (GISTs): Our experience in the management of ...

Maiello(E),Tozzi(L),Latiano(T P),De Bonis(... J Clin Oncol 0000-00-00

19506 Background: GISTs represents 0.1-3% of gastrointestinal neoplasms; most cases occur in people 40 to 80 years old, ...

Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for...

Manegold(C),Thatcher(N),Kortsik(C),Koschel... J Clin Oncol 0000-00-00

...mos (p=.03) and 6.3/8.6 mos; and median time to progression (TTP) was 4.3/2.2 mos and 2.4/3.3 mos. In S3, CRHT occurred ...

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-d...

Blackstock(A W),Socinski(M A),Bogart(J),Gu... J Clin Oncol 0000-00-00

...mos, the med PFS is 7.7 mos and the MST is 13.9 mos. There was a correlation between Gr 3-5 pulmonary toxicity and V ≥ 3...

Phase III randomized study of vinorelbine (V), gemcitabine (G) followed by do...

Kawahara(M),Ogawara(M),Nishiwaki(Y),Kubota... J Clin Oncol 0000-00-00

...mos (p=0.95, Log rank), 13.1 vs 13.8 mos (MST, p=0.28, Log rank), 55.6 vs 55.5%, and 27.6 vs 31.8%. Grade 3/4 toxicities...

Systemic capecitabine and oxaliplatin administered with hepatic arterial infu...

Alberts(S R),Mahoney(M R),Donohue(J),Roh(M... J Clin Oncol 0000-00-00

...mos of follow-up. 6 deaths occurred in less than 2 yrs. 44% (20/45) have recurred, with 40% (8/20) having liver involvem...

Cardiac changes on MRI and SPECT after definitive radiotherapy in patients wi...

Lind(P A),Larsson(T),Lideståhl(A),Thoren(L... J Clin Oncol 0000-00-00

...mos post-RT FUs. They underwent gadolinium enhanced cardiac MRI and rest-SPECT. The mean cardiac (MCD) and left ventricu...

A randomized trial of first-line irinotecan/fluoropymidine combinations with ...

Fuchs(C),Marshall(J),Mitchell(E),Wierzbick... J Clin Oncol 0000-00-00

...mos) was significantly better than for either m-IFL (6.0 mos; p = 0.01) or CapeIri (5.7 mos; p = 0.01). Overall survival...

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs ...

Falcone(A),Masi(G),Brunetti(I),Benedetti(G... J Clin Oncol 0000-00-00

...mos, HR: 0.63, p=0.0006; median S 16.7 vs 22.6, HR:0.70, p=0.032).,The FOLFOXIRI regimen is feasible with manageable tox...

上一页 677 678 679 680 681 682 683 684 685 下一页 681 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]